Recently, BIOYOND Robotics, dedicated to accelerating intelligent automation transformation in the life sciences field, announced the successful completion of its Series A3 funding round worth hundreds of millions of yuan. This round was led by Panthera Capital, with continued investment from Qiming Venture Partners and Boyuan Capital.

Read the Original Text

On October 18, 2024, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. announced that it had recently successfully completed a C1 round of financing worth 300 million yuan. This round of financing was led by China Biologic Products, a well-known domestic industry player, with participation from Pudong Venture Capital and Zhangjiang Haoheng. Existing shareholders Qiming Venture Partners and Shanghai BioPharmaceutical Fund also followed up on their investments. Zhong Lun served as the legal advisor for this round of financing.

Read the Original Text

Recently, Sigma Squares officially completed its Series B financing. This round of financing was led by Topview Capital, with participation from Oriza Ventures, Yahu Investment, Yunhui Capital, Xiangcheng Golden Control Capital, Entropy One Capital, and Boxin Capital, totaling several hundred million RMB.

Read the Original Text

Recently, Union Strong (Beijing) Technology Co., Ltd. secured hundreds of millions in its D+ funding round, led by the Beijing Medical and Health Industry Investment Fund, with participation from the Beijing Economic-Technological Development Zone Industrial Upgrade Equity Investment Fund. This financing not only recognizes the company’s technical capabilities and market potential but also strongly supports Beijing's strategy to build a world-class biopharmaceutical industry cluster, marking a solid step forward for Union Strong® in advancing innovation and development within China’s medical and health industry.

Read the Original Text

Eco Medical's next-generation flow diverter stent "Lattice NEXT" successfully obtained approval for registration from the National Medical Products Administration on October 17, 2024 [Registration Certificate No.: Z20243132086].

Read the Original Text

Recently, the CDE official website showed that the Class 1 new drug HC022 Injection, submitted by Shanghai Hongcheng Pharmaceutical (a subsidiary of Betta Pharmaceuticals), has obtained tacit approval for clinical trials and is intended for the treatment of systemic lupus erythematosus. Data from Menet shows that in 2023, the sales of anti-tumor and immunomodulatory agents (chemical drugs + biologics) in Chinese public medical institutions exceeded 180 billion yuan.

Read the Original Text

Recently, the completion and production launch ceremony of Hunan Calibre Biotechnology Co., Ltd., a wholly-owned subsidiary of Calibre, was successfully held in the Hunan Medical Device Industrial Park.

As the second R&D and production base of Caliber, Hunan Caliber boasts a 2,000-square-meter R&D and production facility, including GMP Class 10,000 and Class 100,000 clean areas, equipment production workshops, testing laboratories, warehouses, and other zones. It has independently developed and launched two KLPMD series liquid chromatography-tandem mass spectrometry detection systems made in China, 13 clinical mass spectrometry reagent products, and seven chromatography column products, all of which have obtained Class II medical device registration certificates. Its official production launch not only represents a crucial step in Caliber's strategic layout but also marks further innovation and development in the field of clinical mass spectrometry for Caliber.

Read the Original Text

Recently, the first batch of implant surgeries using the Netrod® StarBelt™ RDN System were successfully performed under the guidance of Professor Yao Zhifeng from the team of Academician Ge Junbo at Zhongshan Hospital, Fudan University; Professor Wang Xiaozeng from the team of Academician Han Yaling at the General Hospital of the Northern Theater Command of the Chinese People's Liberation Army; Professors Cai Jun and Zhou Yujie’s team members, Professor Li Yueping and Professor Wang Zhijian at Beijing Anzhen Hospital, Capital Medical University; Professor Jiang Jun and Professor Liu Bingchen from the team of Academician Wang Jian’an at the Second Affiliated Hospital, Zhejiang University School of Medicine; the team of Academicians Zhang Yun and Zhang Cheng including Professor Chen Wenqiang, Professor Yang Jianmin, Professor Bu Peili, and Professor Zhong Ming at Qilu Hospital of Shandong University; as well as Professor Xu Jianzhong and Professor Kang Yuanyuan from the team of Professor Wang Jianguo at Ruijin Hospital, Shanghai Jiao Tong University. The surgeries took place simultaneously across five cities—Shanghai, Shenyang, Beijing, Hangzhou, and Jinan—officially marking the beginning of the clinical application chapter for the Netrod® StarBelt™ RDN System.

Read the Original Text

To quickly respond to changes in the global market, Wecare Probiotics proactively established three probiotics research institutes in Suzhou, Wuhan, and Luohe, focusing on breakthroughs in the optimization of mass production processes for bacterial strains. Additionally, the company invested 1 billion yuan in constructing a third-phase factory, achieving the goal of increasing annual production by 600 tons of raw probiotic powder. By introducing internationally advanced equipment and automated production, Wecare successfully reduced raw material costs by 50%, laying a solid foundation for the expansion of the end-market.

Finally, the launch of Weikang's 600 billion highly active preparation solution aligns the development of domestically produced probiotic supplements with international standards. In the future, Weikang will continue to keep up with international frontiers, focus on strain research and intelligent manufacturing, quickly respond to market changes, collaborate with partners, and jointly provide customers with high-quality probiotic products to better serve human health.

Read the Original Text

Recently, Hycan Pharmaceuticals Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the Center for Drug Evaluation of the China National Medical Products Administration, approving the clinical trial of HP568 tablets for the treatment of advanced breast cancer that is estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2- advanced breast cancer). According to available information, as of the date of this report, no similar PROTAC products have been approved for marketing domestically or internationally.

Read the Original Text

RM-101, a gene-editing drug for Usher syndrome independently developed by Ruifeng Bio, received implied approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on October 11, 2024, for its Investigational New Drug (IND) application. This marks that the world's first gene-editing drug for Usher syndrome, developed in China, is about to enter the clinical stage in China, bringing new hope to Chinese patients.

Notably, RM-101 received IND approval from the U.S. Food and Drug Administration (FDA) on September 17 (U.S. time). With this, Refeng Bio has achieved dual IND submissions and approvals in both China and the U.S. for its innovative gene-editing drug targeting Usher syndrome.

Read the Original Text

On October 12, 2024, the semaglutide injection (weight management indication) co-developed by Zhiprotein Biotechnology and Beijing Nuobote Biotechnology Co., Ltd., a wholly-owned subsidiary of Aimeike Technology Development Co., Ltd., received clinical trial implied permission from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

Read the Original Text

On October 26, 2024, RiboX Therapeutics (Shanghai) Biotechnology Co., Ltd. (referred to as "RiboX"), a biotechnology company focused on discovering and developing fully engineered circular RNA therapies, recently announced that its self-developed RXRG001 for radiation-induced xerostomia has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). A Phase I/IIa clinical trial, SPRINX-1, is set to be conducted in the United States. RXRG001 is not only the world's first circular RNA therapy to be granted FDA permission to enter clinical trials but also the only circular RNA drug globally approved for clinical research on radiation-induced xerostomia. This significant progress marks the official entry of circular RNA drugs into the clinical development stage.

Read the Original Text

On October 24, 2024, Shanghai Haihe Biopharma Co., Ltd. and 3SBio Inc. jointly announced that Shenyang Sunshine Pharmaceutical Co., Ltd., a subsidiary of 3SBio, has obtained the exclusive commercialization rights for the oral paclitaxel solution from Normed (Shanghai) Pharmaceutical Technology Co., Ltd., a subsidiary of Haihe Biopharma, in mainland China and Hong Kong, China.

Read the Original Text

On October 16, the Bayer HealthCare Consumer Innovation Cooperation Center was grandly inaugurated at the Shanghai Biomedical Frontier Industry Innovation Center. As a professional enterprise integrating the research, production, and application of probiotic strains, Weikang Probiotics is honored to become a (CCIP) partner.

In the future, Microhealth will deepen cooperation with Bayer in the probiotics field, including technological innovation, industrial integration, and resource sharing, jointly promoting probiotics research and product development to achieve maximum synergy. This collaboration aims to drive new breakthroughs in the health consumer goods sector and offer Chinese consumers more high-quality probiotics products.

Read the Original Text